tirzepatide and autoimmune disorders lupus: what SLE patients need to know GLP1, GIP & Inflammation:What Semaglutide

In June 2021, the FDA approved Wegovy, the first semaglutide drug specifically for weight loss, and in March 2024, it gained approval to reduce the risk of major adverse cardiovascular events in individuals with cardiovascular disease who are overweight or obese

When compared to active treatments as an add-on therapy, semaglutide 14 mg demonstrated superiority to empagliflozin and sitagliptin, and was non-inferior to liraglutide

By handling verification and authorization from the outset, Klinic removes financial uncertainties, supporting you from initial consultation to achieving your weight management objectives

Potential risks include gastrointestinal side effects, such as nausea and constipation, which may be exacerbated by the high-fat content of the keto diet